Navigation Links
EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
Date:6/19/2013

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients. Furthermore, even though elderly patients are occasionally included in clinical trials, those elderly patients who are eventually included are mostly 'healthy' (fit) elderly patients. Thus, the broader elderly patient population is not well represented in clinical trials. The EORTC Cancer in the Elderly Task Force is now starting a new phase 2 trial in precisely this group of patients: EORTC 75111 10114 for non-fit elderly patients with HER-2 positive metastatic breast cancer.

Overall survival for patients with HER-2 positive breast cancer is improved with a combination of chemotherapy and agents that specifically target the HER-2 (human epidermal growth factor receptor 2) gene. Chemotherapy, however, is often accompanied with side effects that can adversely affect health related quality of life in elderly patients. EORTC trial 75111-10114 attempts to find out if HER-2 targeted regimens with minimal toxicity for the elderly population might delay, or even completely obviate, the use of conventional chemotherapy. New HER-2 targeted strategies have created an opportunity to try this strategy.

Patients who progress under pertuzumab and trastuzumab will be allowed to switch to Trastuzumab-DM1 conjugate (T-DM1), another recently available targeted therapy. The binding of trastuzumab to the cell allows intracellular delivery of the cytotoxic agent DM1. The trastuzumab-DM1 conjugate has been shown to have a favorable toxicity profile.

The main objectives of EORTC trial 75111 10114 are to evaluate the efficacy as measured by progression free survival at six months following treatment with pertuzumab combined with trastuzumab or pertuzumab combined with trastuzumab plus metronomic chemotherapy in elderly metastatic breast cancer patients and to select attractive treatments for further development in Phase III. Metronomic chemotherapy uses low doses of chemotherapy drugs so as to minimize toxicity. This EORTC trial will include elderly patients with histologically proven HER-2 positive invasive breast cancer, but might also be suitable for fit (category 1) elderly patients who are wary of the side effects associated with conventional chemotherapy.

Prof. Hans P.M.W. Wildiers, Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Chair of the EORTC Cancer in the Elderly Task Force, and Coordinator of this study says "With these very well tolerated new targeted therapies, we hope to control tumor growth sufficiently long so that toxic chemotherapy would not be needed, and many older patients would more likely die from ageing than cancer."


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
2. EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
3. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
4. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
5. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
6. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
7. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
8. New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz
9. Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments
10. UT Dallas study suggests new approach to fight lung cancer
11. Whooping cough has lifelong health impact, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Today, InhaleLabs.com ... the ingestion of their medication by matching users with high quality water pipes within ... pieces with no commitment. , Inhale was founded by two brothers, Nick and Mike ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: